Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 215

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 215
---
 are regularly provided to the CODM. These expense categories differ from what is disclosed in the Company’s financial results. The table below reconciles the significant expense categories provided to the CODM to the Company’s expenses as disclosed under GAAP (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Revenues$179,516 $168,573 $529,538 $513,713 Less:Adjusted cost of goods sold32,772 37,355 98,025 126,646 Adjusted research and development22,489 17,310 70,276 52,158 Adjusted selling and marketing58,471 43,191 165,006 121,673 Adjusted general and administrative23,180 21,831 70,020 66,097 Goodwill impairment— 163,243 — 163,243 Stock-based compensation13,978 13,230 44,003 38,905 Amortization of acquired intangible assets14,322 14,322 42,966 42,966 Changes in the fair value of contingent consideration625 (3,244)(2,407)(5,541)Legal settlement— — 7,000 — Legal judgment(23,148)— (23,148)— Impairment of acquired IPR&D25,866 — 25,866 — Other4,599 862 15,080 5,641 Total operating expenses173,154 308,100 512,687 611,788           Total other income (expense), net3,162 671 (548)9,443 Income (loss) before income taxes9,524 (138,856)16,303 (88,632)Income tax expense(4,092)(4,610)(10,906)(26,969)Net income (loss)$5,432 $(143,466)$5,397 $(115,601)For information on the Company’s fixed assets located outside of the U.S., refer to Note 6, Fixed Assets.

NOTE 18—SUBSEQUENT EVENTS

In November 2025, the Company and AmacaThera, Inc., or AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced an exclusive worldwide license agreement for the development and commercialization of AMT-143, a